Accuray Incorporated (ARAY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Accuray Incorporated (ARAY) has a cash flow conversion efficiency ratio of -0.134x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.60 Million) by net assets ($41.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ARAY defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Accuray Incorporated - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Accuray Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Accuray Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Accuray Incorporated ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FreeMs Corporation
KQ:053160
|
-0.003x |
|
Jin Yang Pharmaceutical Co. Ltd
KQ:007370
|
0.028x |
|
Freemelt Holding AB
ST:FREEM
|
-0.037x |
|
Centric Holdings S.A
AT:CENTR
|
0.008x |
|
Sprintex Ltd
AU:SIX
|
-0.039x |
|
Ledtech Electronics Corp
TW:6164
|
0.027x |
|
BioXcel Therapeutics Inc
NASDAQ:BTAI
|
0.112x |
|
Bicicletas Monark S.A
SA:BMKS3
|
0.016x |
Annual Cash Flow Conversion Efficiency for Accuray Incorporated (2005–2025)
The table below shows the annual cash flow conversion efficiency of Accuray Incorporated from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Accuray Incorporated worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $81.17 Million | $2.86 Million | 0.035x | +113.34% |
| 2024-06-30 | $45.08 Million | $-11.90 Million | -0.264x | -191.18% |
| 2023-06-30 | $53.66 Million | $15.54 Million | 0.290x | +741.79% |
| 2022-06-30 | $53.19 Million | $-2.40 Million | -0.045x | -108.07% |
| 2021-06-30 | $68.84 Million | $38.51 Million | 0.559x | +2523.42% |
| 2020-06-30 | $63.63 Million | $-1.47 Million | -0.023x | +96.12% |
| 2019-06-30 | $49.87 Million | $-29.64 Million | -0.594x | -257.68% |
| 2018-06-30 | $48.63 Million | $18.33 Million | 0.377x | +4715.74% |
| 2017-06-30 | $46.53 Million | $-380.00K | -0.008x | -101.45% |
| 2016-06-30 | $59.66 Million | $33.54 Million | 0.562x | +354.59% |
| 2015-06-30 | $75.78 Million | $-16.73 Million | -0.221x | -6389.14% |
| 2014-06-30 | $98.55 Million | $346.00K | 0.004x | +100.57% |
| 2013-06-30 | $106.83 Million | $-66.18 Million | -0.619x | -229.90% |
| 2012-06-30 | $203.87 Million | $-38.28 Million | -0.188x | -463.82% |
| 2011-06-30 | $240.33 Million | $12.40 Million | 0.052x | +273.02% |
| 2010-06-30 | $170.08 Million | $-5.07 Million | -0.030x | +42.95% |
| 2009-06-30 | $153.90 Million | $-8.05 Million | -0.052x | +62.00% |
| 2008-06-30 | $130.76 Million | $-17.99 Million | -0.138x | -248.81% |
| 2007-06-30 | $125.44 Million | $11.60 Million | 0.092x | +129.31% |
| 2006-06-30 | $-80.86 Million | $25.50 Million | -0.315x | +1.64% |
| 2005-06-30 | $-56.17 Million | $18.02 Million | -0.321x | -- |
About Accuray Incorporated
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation t… Read more